Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

101.73 +2.79 (+2.82%)
Streaming Delayed Price Updated: 11:48 AM EDT, Mar 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in the William Blair Growth Stock Conference
From Glaukos Corporation
Via Business Wire
News headline image
Tyson Foods, PayPal And 3 Stocks To Watch Heading Into Monday ↗
With US stock futures trading slightly lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
Glaukos Announces FDA Acceptance of NDA Submission for iDose TR
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Expert Ratings for Glaukos ↗
 
Via Benzinga
News headline image
Earnings Preview For Glaukos ↗
 
Via Benzinga
Analyst Expectations for Glaukos's Future ↗
 
Via Benzinga
News headline image
Glaukos Announces First Quarter 2023 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces the Release of its 2022 Sustainability Report
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3
From Glaukos Corporation
Via Business Wire
10 Analysts Have This to Say About Glaukos ↗
 
Via Benzinga
News headline image
What 10 Analyst Ratings Have To Say About Glaukos ↗
 
Via Benzinga
News headline image
Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It ↗
Biomed company Skye Bioscience (OTCQB: SKYE) has seen positive results in its clinical research so far and is preparing for the next stage in the development of its therapy for eye disease.  
Via Benzinga
News headline image
Glaukos Submits New Drug Application to U.S. FDA for iDose TR
From Glaukos Corporation
Via Business Wire
News headline image
NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday ↗
Goldman Sachs boosted the price target for Vir Biotechnology, Inc. (NASDAQ: VIR) from $41 to $53. Goldman Sachs analyst Paul Choi maintained a Buy rating on the stock. Vir Biotechnology shares rose... 
Via Benzinga
News headline image
Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results
From Glaukos Corporation
Via Business Wire
7 Analysts Have This to Say About Glaukos ↗
 
Via Benzinga
News headline image
Analyst Ratings for Glaukos ↗
 
Via Benzinga
News headline image
Glaukos Announces Participation in the Citi Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022 ↗
 
Via Benzinga
News headline image
Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants ↗
This year has been quite busy for Skye Bioscience Inc. (OTCQB: SKYE). 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022 ↗
 
Via Benzinga
News headline image
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday ↗
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5.  Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022 ↗
 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.